Press Release
N.Fans-NFT Aggregation Platform that Adds Value to Global IP based on Blockchain Technology
Global IP encounters major plagiarism and infringement
Traditional artworks and collectibles are faced with many problems such as centralized distribution, solidified industrial model, easy to be copied, lack of fair guarantee and so on. With the development of blockchain technology, its advantages such as tamper-resistant, transparency, and decentralization of data will bring revolutionary innovation to the field of art.
New Future of NFT Brand Digitization
After the release of CryptoKitties in 2017, NFT (abbreviation of “Non-Fungible Token”) entered the public for the first time. CryptoKitties is a decentralized application based on Ethereum. Users can cultivate and collect various electronic cats in the game. Nowadays, high-performance blockchain and layer 2 solutions continue to emerge. So under various scaling schemes, high-throughput DAPP has realized real applications. And the attention of collectors and artists has returned to the NFT domain. In 2021, the wave of digital economy spreads all over the world: a digital collection card made of classic dunk shots made by the famous Los Angeles Lakers star Le Bron James sold for a high price of 208,000 US dollars; Christie’s sold the digital artwork created by artist Beeple for a record price of $69.3 million (approximately $450 million). The latest figures show that NFT sales exceeded $2 billion in the first quarter of this year, with 20 times increase over the previous quarter.
One of the most well-known application scenarios of NFT is to allow artists to use tokens to represent the ownership of their digital artworks, which can greatly enhance the value of artworks. Nowadays, the online art market is centralized, and the operation process is not transparent, and the platform squeezes a lot of value from it. Creators have to pay huge fees to launch their works on the platform, and they can only blindly trust that the platform will display and distribute their works fairly. With NFT, artists can easily sell their digital art and get income from selling NFT on the secondary market. This is a sustainable economic model.
NFans Celebrity Digital Collection Platform based on Blockchain
The Singapore AVF Foundation and the NFANS platform are fully cooperating to enter the NFT field. N.Fans is a new blockchain digital collection game platform for Japanese celebrities, including photos of various well-known artists, Moment creating and sales, NFT and other fields of well-known cartoons, realizing the application of NFT in popular, entertainment and other fields. It also serves and helps fans’ NFT to circulate, confirm rights to build a trading platform for global participants.
AVF Foundation Singapore has announced that its artists will be joining N.ans to launch NFT products. AVF has signed many famous celebrities, such as Hata Noksuki, Mitsukami Yoshiki, Sakishima Shinki, Sakyamatsuki Takatsuki, Kushima Misoand other artists. At the same time, N.Fans is endorsed by a Japanese head office, and has been joined by well-known artists such as Hatano Yui. N.Fans-Invested by many top investment institutions in the world. At present, N.Fans has been led by investment institutions such as BIP32 Venture, Seven o’clock, Krypto Fund, ETFDAO Fund, etc. N.Fans builds a complete application ecosystem around NFT. At present, it includes comprehensive NFT asset trading section, NFT asset mortgage and lending, NFT INO issuance, and NFT blind box.
N.Fans-NFT Aggregation Platform that Adds Value to Global IP based on Blockchain Technology
N.Fans is the world’s first brand and IP-oriented NFT digital aggregation platform based on blockchain thinking and technology, with “user-centric” and “digital co-creation” as the core concept. Through the new digital technology of blockchain to build the new digital models and practical cases. This is not only the upgrade of digital scene services and the new exploration of digital marketing, but also a big attempt of global brand and IP digitalization, making a contribution to the global IP digitalization.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
STARTRADER Breaks Ground on Davao Basketball Court Revamp in the Philippines, Benefiting Around 20,000 People
Davao City, Philippines, July 10th, 2026, FinanceWire
The project marks STARCARES’ latest CSR investment in accessible sports infrastructure for schools and communities.
STARTRADER has officially launched the redevelopment of the basketball court at Communal Elementary School in Buhangin, Davao City, with a groundbreaking ceremony held on site. Upon completion, the upgraded facility will benefit approximately 20,000 students, school staff, parents, and residents. It will serve approximately 2,000 learners, 72 school staff, 1,600 parents, and approximately 16,000 residents of Barangay Communal
The project responds to the need for a functional, well-maintained recreational space serving both Communal Elementary School and the wider Barangay Communal community. For students, it supports physical education, school assemblies, and organized sports. For residents, it provides a reliable venue for recreation and community activities. In a country where basketball brings people together, the upgraded court is designed to serve both groups equally.
The initiative builds on STARCARES’ growing global commitment to youth development through accessible sports infrastructure. Following successful basketball court revitalization projects in Vietnam and Thailand, the Philippines marks the next step in creating spaces where youth can learn, play, and grow.
“Breaking ground on this project is just the beginning. STARCARES exists to create lasting impact, and this court will provide thousands of students and residents in Buhangin with a safe, dependable place to learn, play, and come together for years to come.” Peter Karsten, CEO of STARTRADER.
“We are excited to see this project take shape. It will give our learners a safe space to grow, be active, and build confidence while bringing our community together during weekends. We are deeply grateful to STARTRADER and STARCARES.” Nelson Sepe Lubguban Jr., Principal of Communal Elementary School.
Looking ahead, STARCARES will expand its global basketball court initiative, with Lagos, Nigeria planned as the next redevelopment project, furthering its mission to create safe, inclusive sports spaces that empower youth and strengthen communities worldwide.
About STARTRADER
STARTRADER is a global multi-asset broker empowering retail and institutional partners to access global markets through a range of platforms, including MetaTrader, STAR-APP, and STAR-COPY.
Regulated in five jurisdictions (CMA, ASIC, FSCA, FSA, and FSC), STARTRADER combines strong governance with a client-first approach, serving both retail clients and partners with a commitment to transparency, reliability, and long-term growth.
Contact
Janna Magabilen
Janna.magabilen@startrader.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Philip Ashton-Rickardt Says the Next Generation of Medical Breakthroughs Will Need More Scientist-Entrepreneurs
-
Boston biotech leader Philip Ashton-Rickardt believes more researchers should take their discoveries beyond the laboratory and into the real world, where they can improve lives.
Massachusetts, USA, Jul 10, 2026, ZEX PR WIRE — Philip Ashton-Rickardt, Managing Director and Chief Scientific Officer of BE Therapeutics, is encouraging more scientists to consider entrepreneurship as part of their career journey, arguing that the next generation of medical breakthroughs will depend not only on scientific discovery but also on the people willing to transform those discoveries into real-world treatments.
After more than two decades in academia, including professorships at the University of Chicago and Imperial College London, Ashton-Rickardt decided to leave university research and enter biotechnology. Since then, he has founded and helped lead multiple companies in developing advanced cell therapies for neurological diseases, driven by a desire to move promising science closer to patients.
“The goal was never simply to publish another paper,” said Ashton-Rickardt. “I wanted to help build therapies that could eventually improve people’s lives. That meant stepping outside my comfort zone and learning an entirely new way of thinking.”
His message comes as more researchers look beyond traditional academic careers. According to the Association of University Technology Managers (AUTM), U.S. research institutions launched more than 1,100 startups based on university discoveries in 2023, reflecting growing momentum to translate scientific research into real-world products and therapies. Ashton-Rickardt believes that trend is especially important in biotechnology, where scientific discoveries often need entrepreneurial leadership to reach patients.
“An idea only becomes valuable when people work together to test it,” he said. “Science doesn’t move forward because one person has all the answers. It moves forward because people with different expertise challenge each other and build something better together.”
Ashton-Rickardt believes scientists often possess many of the qualities needed to become successful entrepreneurs, even if they don’t always recognise it. Years spent solving complex problems build resilience, curiosity, adaptability, and the ability to learn from failure. Those same qualities are essential for creating companies capable of translating discoveries into therapies.
“I’ve never been afraid to leave my comfort zone,” he said. “Every major step in my career felt uncertain at the time, but those decisions opened opportunities I never could have planned.”
Growing up in a working-class family in the United Kingdom also shaped his outlook. He says learning to create his own opportunities gave him the confidence to move between academia, startups, and leadership roles across the biotechnology industry.
“We sometimes think we have to choose between being a scientist and being an entrepreneur,” Ashton-Rickardt said. “I don’t see those as competing paths. I see entrepreneurship as another way of applying science to solve important problems.”
He also believes curiosity remains one of the most valuable qualities any scientist can develop.
“The moment you think you’ve learned enough is usually the moment you stop growing,” he said. “The best scientists and the best entrepreneurs never stop asking questions.”
Looking Ahead
Ashton-Rickardt hopes more scientists will see entrepreneurship as a natural extension of research rather than a departure from it. While publishing discoveries remains an important part of scientific progress, he believes researchers should also think about how those discoveries can become products, therapies, and technologies that improve people’s lives.
“If you have an idea that could genuinely make a difference, don’t assume someone else will take it forward,” Ashton-Rickardt said. “Stay curious, keep asking questions, and don’t be afraid to build something new.”
About Philip Ashton-Rickardt
Philip Ashton-Rickardt is the Managing Director and Chief Scientific Officer of BE Therapeutics. A molecular immunologist by training, he earned his PhD from the University of Edinburgh before completing postdoctoral research at the Massachusetts Institute of Technology. After distinguished academic careers at the University of Chicago and Imperial College London, he transitioned into biotechnology entrepreneurship, founding and leading multiple companies focused on developing innovative cell therapies for neurological and immune-related diseases. He has also held leadership roles at Sigilon Therapeutics, Flagship Pioneering, and Halyard Therapeutics. Today, his work focuses on advancing engineered cell therapies that have the potential to improve the treatment of neurological disorders while helping bridge the gap between scientific discovery and real-world patient care.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Vantage Vascular is one of just over 10 U.S. practices chosen to participate in the landmark RESORB clinical test for knee osteoarthritis pain.
Brooklyn, NY, United States, 10th Jul 2026 – Vantage Vascular, an outpatient vascular and interventional radiology practice serving patients across New York and New Jersey, has been selected as one of just over 10 leading U.S. clinical sites chosen to participate in the RESORB clinical test, a landmark national study evaluating a breakthrough, non-surgical treatment for knee osteoarthritis pain.
Being named a RESORB test site is not automatic. NEXTBIOMEDICAL, the study sponsor, specifically sought out practices with the clinical expertise, imaging capabilities, and patient-first infrastructure to effectively conduct a pivotal FDA test.
RESORB (Randomized Controlled Study Evaluating Genicular Artery Embolization Against Intra-Articular Corticosteroid Knee Injection for Osteoarthritic Knee Pain) is a pivotal, FDA-approved clinical test comparing genicular artery embolization (GAE) using an investigational device called Nexsphere F to a standard corticosteroid knee injection. The test is enrolling approximately 126 patients across more than 10 U.S. sites and is registered on ClinicalTrials.gov as NCT06872567.
Genicular artery embolization is a minimally invasive, outpatient procedure in which board-certified interventional radiologists use image guidance to deliver tiny particles into blood vessels feeding the inflamed tissues of the knee.
Nexsphere F is a novel, fast-resorbable microsphere technology. Unlike permanent embolic agents, Nexsphere F microspheres dissolve naturally within 2 to 6 hours after the procedure.
Term blockage of blood flow. The device has already received FDA Breakthrough Device Designation, CMS IDE Category B approval (meaning Medicare covers the procedure during the test), and CE-MDD certification in Europe, where it has been used in thousands of procedures with a strong safety record.
Why Being a Selected test Site Matters for Patients
Clinical test site selection for an FDA pivotal study is highly competitive. Sponsors identify practices based on physician expertise, procedural volume, imaging infrastructure, and the ability to safely manage research protocols.
For patients, what this means in practice is significant: Vantage Vascular is offering access to a treatment not yet available anywhere outside of these select test sites in the United States. If you have knee osteoarthritis pain that has persisted despite medications and conservative care for at least two months, and you are not currently planning knee surgery or replacement, you may be eligible to receive this FDA-monitored, cutting-edge procedure at no cost through the test.
The test’s national Principal Investigator and Chief Medical Officer for NEXTBIOMEDICAL is Dr. Ziv J. Haskal, MD, Professor of Interventional Radiology at the University of Virginia. The clinical evidence behind Nexsphere F continues to grow: a published study in the Journal of Vascular and Interventional Radiology evaluating 155 patients treated with resorbable microspheres found a 67% average reduction in pain at 6 months, with no device-related serious adverse events.
Who May Be Eligible
The RESORB test is enrolling adults who:
• Have knee osteoarthritis pain that has not responded adequately to conservative treatments for at least 2 months
• Are not currently planning knee surgery or knee replacement
• Meet the study’s eligibility criteria as reviewed by Vantage Vascular’s clinical team
If enrolled, participants are randomly assigned to receive either GAE with Nexsphere F or a corticosteroid knee injection. Those initially assigned to the corticosteroid injection have the option to receive GAE after 180 days. The test runs approximately 12 to 18 months, and participation is always voluntary.
The test is FDA-IDE and IRB-approved (IRB approval at the protocol level: October 31, 2025). During the test, the procedure is covered under CMS IDE Category B, meaning Medicare-eligible patients may have coverage for test participation.
Schedule a Consultation at Vantage Vascular
If you or someone you know has been living with chronic knee pain, now is the time to explore whether you qualify. Vantage Vascular’s team will evaluate your history, imaging, and treatment background to determine eligibility and walk you through every step of the process with the same compassionate, patient-first care the practice is known for.
Enrollment is currently open at Vantage Vascular’s Brooklyn and New Jersey locations. Call or visit the practice online to schedule a consultation.
Brooklyn Flatlands Clinic: 2035 Ralph Ave, Suite B5, Brooklyn, NY 11234
Brooklyn Midwood Clinic: 603 Rugby Road, Suite 3, Brooklyn, NY 11230
New Jersey Fair Lawn Clinic: 15-01 Broadway, Suites 1–3, Fair Lawn, NJ 07410
NY: (718) 247-8794 | NJ: (201) 812-2929 | Monday–Friday: 8AM–6PM | vantagevascular.com
About Vantage Vascular
Vantage Vascular is an outpatient vascular and interventional radiology practice with locations in Brooklyn, New York and Fair Lawn, New Jersey. Led by Dr. Vishal K. Sinha, MD (Founder & President) and Dr. Christopher M. Harnain, MD, MBA, RPVI (Chief of Interventional Radiology & Founding Member), the practice’s Ivy League-educated, board-certified interventional radiologists deliver world-class, minimally invasive treatments for joint pain, vascular conditions, women’s health, and more — all in a comfortable outpatient setting, with no hospital stays or prolonged recovery. Vantage Vascular is dedicated to advancing patient care through innovation, clinical excellence, and a deep commitment to the communities of New York and New Jersey.
About the RESORB test
RESORB is a randomized, open-label, FDA-IDE and IRB-approved pivotal clinical test evaluating genicular artery embolization with Nexsphere F against intra-articular corticosteroid knee injection for osteoarthritic knee pain. The study is registered on ClinicalTrials.gov as NCT06872567, with an estimated enrollment of 126 participants at more than 10 leading U.S. clinical sites. Nexsphere F has received FDA Breakthrough Device Designation, CMS IDE Category B approval, and CE-MDD certification in Europe.
Important Research Notice
Nexsphere F is an investigational device not yet approved or cleared by the FDA for commercial use in the United States. It is available only through the RESORB clinical test at authorized test sites. Participation is subject to eligibility criteria, informed consent, site availability, and investigator review. Individual results may vary. Medicare coverage under CMS IDE Category B applies to eligible participants during the test period; patients should confirm coverage with Vantage Vascular and their insurer.
Media Contact
Organization: Vantage Vascular
Contact Person: Vishal K. Sinha
Website: https://vantagevascular.com/
Email: Send Email
Contact Number: +17182478794
Address:2035 Ralph Ave Ste B
City: Brooklyn
State: NY
Country:United States
Release id:46614
The post Vantage Vascular Selected for National RESORB Knee test Brooklyn NY and Fair Lawn NJ appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
STARTRADER Breaks Ground on Davao Basketball Court Revamp in the Philippines, Benefiting Around 20,000 People
Vantage Vascular Selected for National RESORB Knee test Brooklyn NY and Fair Lawn NJ
Philip Ashton-Rickardt Says the Next Generation of Medical Breakthroughs Will Need More Scientist-Entrepreneurs
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release7 days ago
Community Hero Who Dedicated His Life to Helping Others Now Needs Help After Devastating Fire Loss
-
Press Release4 days ago
HOPE AI and OHGI Explore the Role of Artificial Intelligence in Preparing Future Generations
-
Press Release7 days ago
California HOA Law Changes Prompt First Equity Management to Guide Communities Through New Fine Limitations
-
Press Release21 hours ago
Vincere Portfolios Highlights Growing Shift Toward Algorithmic Futures Trading Among Independent Investors
-
Press Release7 days ago
Jaadugar A Witch in Mongolia Set to Premiere with QUEEN BEE STAR Ending Theme, New PV and Visual
-
Press Release6 days ago
Fifsee Brings FIFSCORE, AI Studio and Personalized AI Real Estate Intelligence to 118 Countries
-
Press Release5 days ago
PostOnce Launches Crossposting Tool to Help Creators Automatically Post Once and Publish Everywhere
-
Press Release6 days ago
CEMOTO D Series Electric Dirt Bike: Zero-Emission Off-Road Adventure